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Incidence and Severity of Acute Allograft 
Rejection in Liver Transplant Recipients 
Treated With Alfa Interferon 
Ashokhumar jain, Anthony J. Demetris, Rafael Manez, 
Athanassisos C. Tsamanadas, David Van Thiel, jorge Rakela, 
Thomas E. Starzl, and john J. Fung 
Interferon alfa-2b (IFN-o) therapy has been shown 
to be effective in the treatment of viral hepatitis B 
(HBV) or viral hepatitis C (HCV) in patients who 
did not undergo transplantation. However, in allo-
graft recipients, treatment with IFN-o often leads 
to allograft rejection. The aim of the present study 
was to determine if IFN-o therapy increases the 
incidence or severity of acute rejection in human 
liver allograft recipients. One hundred five ortho-
topic liver transplant (OLT) recipients with HBV 
(n = 32), HCV (n = 58), or Non A Non B Non C (n = 
15) viral infections were treated with a 6-month 
course of IFN-o, 5 million U subcutaneously three 
times a week, which began 2 to 97 months after 
transplantation. The mean hepatitis activity index 
(HAl) at the beginning of the therapy was 10.1 ± 
3.0. The baseline immunosuppression was 
achieved by tacrolimus in n patients and by 
cyclosporine A (CyA) in 28 patients. Contempora-
neous controls consisted of 132 OLT patients (100 
who received tacrolimus and 32 who received 
CyA) who did not receive IFN-o. A retrospective 
analysis was performed on this group of patients. 
The incidence of rejection and the baseline immu-
nosuppression were compared. All biopsies were 
reviewed without knowledge of clinical data and 
R ecurrent infection with either hepatitis B virus (HBy)I-4 or hepatitis C virus (HCy)S·7 is an 
important cause of allograft dysfunction after ortho-
topic liver transplantation (OlT). As first reported 
by Corman et all and confirmed many times since, 
these hepatitides can progress to end-stage liver 
disease and allograft failure. The accelerated pro-
gression of recurrence with second transplants3.4 
has called into question the probity of retransplan-
tation as an option in such cases. 
Interferon alfa-2b (IFN-o) therapy has been 
shown to be effective for viral hepatitis caused by 
HBy8 or HCy<i·13 in nonimmunosuppressed pa-
tients. This treatment has been less effective in 
virally infected liver allograft recipients. 14.ltI Further-
more, IFN-o is known to increase the expression of 
human lymphocyte antigen class 119.20 and may 
lead to allograft rejection. III This concern has been 
scored for HAl and for rejection activity index 
(RAI). The biochemical response to IFN-o was 
also examined. The mean baseline maintenance 
dose of prednisone was greater by 2 mg daily in 
patients who received IFN-o with tacrolimus com-
pared with control patients who did not receive 
IFN-o with tacrolimus (IFN-o 5.3 ± 5.2 mg daily v 
controls 3.3 ± 4.9 mg daily; P s; .05). Similarly, the 
mean maintenance dose of prednisone was 
greater by 2.5 mg daily in patients who received 
IFN-o compared with controls who received CyA-
based immunosuppression (IFN-o 9.8 ± 3.1 mg 
daily v controls 7.3 ± 3.3 mg daily; P = .01). Acute 
rejection episodes were detected in 10.5"10 (n = 
11) of IFN-o-treated patients compared with 8.8"10 
of controls for the similar time period from OLT 
and period of exposure to risk of rejection. Mean 
RAI was 2.0 ± 2.4 for the IFN-o-treated group and 
2.1 ± 1.7 for controls. Rejection episodes with 
IFN-o treatment were mild and responded to ste-
roid therapy. In OLT reCipients, the risk of acute 
rejection was not increased by the introduction of 
IFN-o. However, in this study, patients were ex-
posed to greater levels of immunosuppression. 
Copyright © 1998 by the American Association for 
the Study of Liver Diseases 
reinforced by the induction of rejection with IFN-o 
in experimental animals,21 and by reports of irrevers-
ible episodes of acute renal allograft rejection in up 
to 29% of humans treated prophylactically with a 
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course of this cYlOkine for cytomegalovirus,Z2,21 
and even more frequently when kidney transplant 
recipients were treated for hepatitis, H 
The aim of the present study was to determine 
whether, and to what extent, IFN-a treatment 
increased the incidence and severity of acute rejec-
tion episodes in human liver allograft recipients, 
Because it is well known that the incidence of both 
acute allograft rejection and viral replication are 
influenced by the level of immunosuppression, the 
doses and blood plasma levels of the immunosup-
pressive drugs before and during IFN-a treatment 
were compared with those in control OlT recipi-
ents who did not have hepatitis and did not receive 
IFN-a, 
Patients and Methods 
Between March 1990 and June 1992, 105 OLT recipients 
were treated with IFN-Cl for HBY (n = 32; 30,5%), HCV 
(n = 58; 55,2%), or hepatitis Non A Non B Non C (n = 
15; 14.3%). Fifty-seven patients (56,2%) underwent 
transplantation in the 1980s, and HCY serology was not 
available, However, 20 of 32 patients (62,5%) from the 
HBY group, 33 of 58 patients (56,9%) from the HCV 
group, and 6 of 15 patients (40%) from the Non A Non B 
Non C group had documented diagnoses of HBY, HCY, 
and Non A Non B hepatitis before OlT, respectively. 
They were considered to be recurrences of the original 
disease, whereas the remaining 46 patients could have 
had either recurrent or de novo hepatitis, A retrospective 
study was performed on these 105 patients for the 
incidence and severity of acute rejection and baseline 
immunosuppression, The results were compared with a 
contemporaneous control group of 132 OLT recipients 
who did not receive IFN-a, 
Diagnosis of Virus Infection 
The pre transplantation diagnosis of HBY infection was 
made by the detection of hepatitis B surface antigen 
(HbsAg) in the serum. Before accepting the diagnosis of 
recurrent (or de novo) posttransplantation viral hepatitis 
in the allograft. all increases in liver enzyme levels, with 
or without an increase in the serum bilirubin level, were 
investigated with a liver biopsy and a Doppler ultrasound 
examination of the liver to determine the patency of 
hepatic vessels and the configuration of the biliary tract. 
A cholangiogram was performed whenever clinically 
indicated. 
Recurrent HBY was diagnosed by the presence of 
HbsAg in the serum and expression of HbsAg and 
hepatitis B core antigen (HbcAg) by liver cells by means 
of immunoperoxidase techniques on bIOpsy specimens. 
A diagnOSis of HCY infecnon was made bv detection of 
anti-HCY antibodies by either a first-generation enzyme-
linked assay (Ortho Diagnostic. Raritan. NJ) or second-
generation enzyme-linked assay (Abbott 100, Abbott 
Park Road. IL) and confirmed by reverse-transcriptase 
polymerase chain reaction in a minority of liver biopsies, 
The diagnosis of Non A Non B Non C hepatitis was made 
when serum aminotransferase levels were elevated and 
there was histologic evidence of hepatitis. The histopatho-
logic criteria included a ponal and parenchymal mono-
nuclear cell infiltrate and diffuse spotty hepatocyte 
necrosis without significant bile duct damage and the 
absence of any serologic evidence of hepatitis A, B. C. or 
D. cytomegalovirus. Epstein-Barr virus. or herpes sim-
plex virus infection. All biopsies in the treatment and 
control groups were reviewed by pathologists who had 
no knowledge of treatment regimen or clinical course. 
These were scored for hepatitis activity index (HAl) by 
using Knodell's system15 and rejection activity index 
(RAJ) by international consensus document26 All pa-
tients who received additional bolus doses of steroids 
and showed biochemical improvement in liver function 
were considered as rejection in both groups, The biopsies 
were also scored for RAI in both groups for comparison. 
Immunosuppression 
Two different postoperative regimens were used. One 
Cn = 52) was based on tacrolimus (FKS06) and low-dose 
prednisone.27 The second (n = 53) was based on 
cyclosporine-A (C y A) and generally higher doses of 
prednisone, to which azathioprine was frequently added. 27 
Twenty-five of 53 patients started on CyA therapy were 
subsequently converted to tacrolimus therapy 12 :!: 7 
months before IFN-a therapy was initiated. Thus, there 
were 77 patients who received tacrolimus and 28 who 
received CyA at the time IFN-Cl treatment was started. 
The results of IFN-a treatment were stratified in these 
two cohorts. Rejection episodes occurring with either 
regimen were treated with a I-g methylprednisolone 
bolus or with 1 g of hydrocortisone alone, with or 
without a tapered burst of methylprednisolone (total. 
600 mg over 5 days); steroid-resistant rejection was 
treated with 5 to 10 mL per day of OKT3 (Ortho Biotech. 
Raritan. NJ) for 5 to 14 days.28 
Interferon Therapy 
Patients were taught to give their own subcutaneous 
injections of 5 million U of IFN-a three times per week. 
The IFN-a course began 2 to 97 months posuransplanta-
tion. In 27 of 105 patients (25,7%), the dose of IFN-a 
was reduced because of leukopenia (n "" 1 0) and various 
combinallons of thrombocytopenia, anorexia. fatigue. 
weight loss. weakness. or malaise. 
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Table 1. Liver Function Before and After IFN'a Therapy 
Total Bilirubin 
(mg/dl) AST(U/l) AlT (Ull) GGT(Ull) AP (UlL) 
Before After Before After Before After Before After Before After 
Nonresponder 
(n; 70) 1.2 = 1.1 1.6 = 3.6 163 = 163 138 = 93 177 = 159 139 = 90 359 = 811 400 = 591 210 = 211 182 = 171 
Complete 
responder 
(n; 35) 1.0 = 0.6 0.8 = 0.7 139 = 99 42 = 26 139 = 167 33 = 10 351 = 376 184 = 233 192 = 121 116 = 67 
NOTE. All values expressed as mean = standard deviation. 
Abbreviations: AST. Aspartate aminotransferase; ALT. Alanine aminotransferase; GGT. Gamma-glutamyltransferase; 
AP. Alkaline phosphatase. 
A complete biochemical response to IFN-a was 
defined as a normalization of the serum alanine amino-
transferase level at the end of 6 months of IFN-a therapy. 
All others were considered nonresponders. 
The control patients also were stratified according to 
immunosuppression. There were 100 consecutive con-
temporary tacrolimus-treated primary liver transplant 
recipients who survived at least 3 postoperative months, 
and 32 similar recipients who received CyA-based immu-
nosuppression. 
Because the incidence of acute allograft rejection 
varied with the postoperative time,21·2B the treatment 
group who received tacrolimus and their companion 
controls were divided into three subgroups, defined by 
the interval between OLT and the initiation of IFN-a. 
Patients treated with IFN-a while on CyA were 11 to 
97 months posttransplantation (mean, 42 months). These 
patients and their 32 non-hepatitis-infected controls had 
a similar range of follow-up. 
Analytic Methods and Statistics 
The tacrolimus dose and plasma trough level and the 
prednisone dose were recorded before, at the 3-month 
midpoint. and at the end of IFN-a treatment. For each 
time point, the values for the IFN-a-treatment sub-
groups were compared with the controls by using the 
nonparametric Mann-Whitney U test. All results were 
expressed as mean :±: standard deviation. P less than .05 
was considered significant. 
Results 
Response Rate of Hepatitis 
Thirty-five of the 105 patients (33%) with hepatitiS 
had a complete biochemical response to the 6-
month IFN-a course. Table 1 lists the liver func-
tion tests and clinical response classifications be-
fore and after the 6-month IFN-o: therapy. The rate 
of complete biochemical response was 40% with 
Non A Non B Non C hepatitis, 38% with HCY, and 
22%withHBV 
These treatment benefits were not evident in the 
HAl scores by means of the Knodell's system.25 In 
47 patients who had serial biopsies, the mean 
IFN-a HAl score was 10.1 ± 3.0 before and 10.9 ± 
4.1 after the IFN-a treatment. 
Nine of the 35 patients (25.7%) who showed a 
complete biochemical response relapsed within 6 
months of stopping treatment. Biochemical relapse 
rates for the Non A Non B Non C. HCY, and HBV 
groups were 16.6%, 27%, and 28.5%, respectively. 
These were treated with further courses ofIFN-a. 
Incidence and Severity of Allograft 
Rejection 
There were 11 episodes (10.5%) of acute allograft 
rejection in the IFN-a group during the 6 months 
Table 2. Changes in Liver Function With Acute Rejection 
Rejection Total Bilirubin (rng/dL) AlT (Ull) AST(Ull) GGT (U/l) AP(Ull) 
Before 0.8 = 0.7 302 = 148 170 = 171 194 = 158 70 = 127 
During 1.4 = 1.0 406 = 251 306=191 513 = 322 196 = 85 
After anti rejection therapy 0.8:!: 0.5 116 = 107 93:!: 61 246 = 84 144 = 70 
NOTE. Values are expressed as mean:!: standard deviation. 
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that required additional antirejection medication 
and showed an improvement in biochemical param-
eter of liver inJuI)' (Table 2). These episodes were 
controlled with 1 g of methylprednisone (nine 
occasions) or 1 g of hydrocortisone (two occa-
sions). No OKT3 treatment was required and no 
graft was lost from acute rejection. 
Table 3. Incidence of Liver Allograft Rejection 
in IFN-a and Control Patients 
IFN-o Control 
Patients Patients 
Rejection/ Rejection/ 
Time After Patients Patients 
Transplantation Exposed Exposed 
(months) to Risk (%) to Risk (%) 
Tacrolimus 
2-12 6/43 (14%) 15/100 (15%) 
12-24 3/22 (14%) 9/95' (9%) 
24-36 0/12 (0%) 2193' (2%) 
Cyclosporine 
42-48 2128 (7%) 2132 (6%) 
Total 11/105 (10.5%) 28/320t (8.8%) 
Rejection Activity 
Index 2.0::t 2.4 2.1 ::t 1.7 
'The decrease in the number of control patients is 
because of the deaths that occurred during that 
period of time. 
tTotal number of exposures over the interval. 
The mean time from the initiation of IFN-a 
treatment to onset of acute rejection was 12.4 :!: 5.3 
weeks (range. 4 to 19 weeks). An example of an 
acute rejection episode that occurred during IFN-a 
treatment and response to 1 g of methylprednisone 
is shown in Figure 1. The mean RAI scores of the 
biopsies with rejection were 2.0 :!: 2.4 (range. 0 to 
6). In the control group. 8.8% of the patients ex-
perienced episodes of rejection that reqUired addi-
tional antirejection treatment. The mean RAI in 
this group was 2.1 :!: 1.7 (range. 0 to 6) (Table 3). 
Patterns of Immunosuppression 
IFN-a and recurrent hepatitis with lacrolimus therapy. 
The deviations from control management for the 
77 transplant recipients who received IFN-a for 
recurrent hepatitis are shown in Figure 2. Frequent 
Figure 1. (A) An example of a patient with chronic 
hepatitis, showing portal lymphocytic Inflamma-
tion with mild interface activity. Note the lack of 
bile duct damage and endothelltls of portal veins. 
(8) This patient experienced an episode of acute 
rejection during IFN-a treatment. Note that the 
portal mononuclear inflammation is now directed 
at the bile ducts and portal vein endothelitis has 
appeared. (C) After 1 g of methylprednisone, the 
portal Infiltrate has lessened and the duct damage 
and endothelitls have largely disappeared. There 
is, however, some residual interface activity (he-
matoxylin-eosin stain x200). 
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reductions were made in the tacrolimus dosages 
(Fig 2A) because of high blood levels of tacrolimus 
secondary to hepatic dysfunction (Fig 2B). These 
dose reductions were most dramatic when the 
recurrent hepatitis developed early posttransplanta-
tion. With the dose reductions, the elevated plasma 
trough concentrations of tacrolimus decreased 
thereafter into the general range of the non-
hepatitis-infected controls (Fig 2B). 
A countervailing adjustment that preceded the 
beginning of IFN-o. therapy was an increase in the 
daily prednisone doses, presumably to cover the 
possibility that rejection (rather than hepatitis) was 
responsible for the hepatic dysfunction (Fig 2C). 
The average steroid doses remained significantly 
greater throughout the 6 months of IFN-o. treat-
ment (Fig 2C). Overall, tacrolimus-treated patients 
received 2 mg more steroids daily during the IFN-o. 
Months after Transplantation 
treatment than the non-IFN-o. controls (mean, 
5.3 ::!: 5.2 mg v 3.3 ::!: 4.9 mg; P = .05). 
IFN-o. and recurrent hepatitis with CyA therapy. The 
same patterns with either prompt or delayed reduc-
tions of eyA and azathioprine doses and increases 
in prednisone dosage were evident compared with 
the non-hepatitis-infected control groups (Table 
4). The dose of prednisone in the IFN-a-treated 
group who received CyA was 2.5 mg greater daily 
(P = .01) than the dose used in the group who did 
not receive IFN-o. (Table 4). 
Discussion 
Whether IFN-o. increases the risk of hepatiC allo-
graft rejection has been an unresolved controversy. 
Feray et alit> noted a high rate of chronic rejection 
in IFN -a-treated patients with HCV Dousset et al H 
zoz Jalll cl £II 
Table 4. Immunosuppression of CyA-Treated Patients 
Immunosuppression Control (n = 32) 
CyA dose (mg/kgld) 4.6:!: 2.5 
CyA level (ngimLlt 342:!: 254 
Prednisone (mglmLlt 7.3:!: 3.8 
Azathioprine (mgld) 28.1 :!: 35.2 
<P < .05 = compared to control. 
tFluoroscein polarization immunoassay. 
reported that 2 liver transplant recipients lost their 
grafts to acute chronic rejection that appeared to be 
associated temporally with IFN-o: treatment. How-
ever, both of these patients were maintained on 
lower-than-usual doses and blood levels of CyA. 
We have observed the same chain of events in 
individual cases, but in our cumulative experience 
reported here, blood levels of tacrolimus and CyA 
remained greater than in the control patients, even 
though the doses of these immunosuppressants 
were frequently reduced after IFN-o: therapy began 
(Fig 2 and Table 4). 
All clinical and pathological rejections were 
counted in each group; however, the increase in 
frequency of acute hepatic rejections was not 
observed in the IFN-o: group compared with the 
control group, confirming previous claims by Hopf 
et aJiB and Wright et al. 1S.17 Also, RAI scores were 
comparable for the IFN-o:-treatment and control 
groups. There is no reason, however, to deny the 
inherent ability of IFN-o: to tip the scales toward 
rejection. This has been well documented in experi-
mental models21 and by reports of the devastating 
complications of IFN-o: therapy in human kidney 
transplant recipients,22.23 including some of our 
own patients. 24 
The most obvious explanation for the disparity 
in outcome with liver and kidney transplantation 
derives from the retarded metabolism of tacro-
limus29.3o and, to a lesser degree, CyA, that occurs 
with the hepatic dysfunction that is a frequent 
finding in the post-OLT population, especially so 
with the supervention of hepatitis. The near dou-
bling of plasma (or blood) levels of the antirejec-
tion drugs in the IFN-o:-treated group as well as 
the tendency to increase prednisone doses (Fig 2C) 
in response to hepatic dvsfunction presumably 
interdict an undesirable IFN-o: effect on rejection. 
The greater resistance of the liver to rejection 
IFN'a Treatment (n + 28) 
Before During After 
4.9:!: 5.0 3.4:!:1.9< 3.3 :!: 2< 
475 :!: 314 411 :!: 245 474:!: 352 
9.8 :!: 4.0< 9.8 :!: 3.1< 9.6 :!: 3.4< 
22.6 :!: 33.7 8.7 :!: 22.5 7.7:!: 18.4< 
compared with other organs31 or an inherent im-
mune depression caused by the hepatitis virus32·34 
are less likely contributory factors. 
The difficulties of balancing immunostimulant 
(IFN-o:) with immunosuppressive therapy are too 
self-evident to belabor, except to note that the 
information available in our study precluded their 
precise quantitation of these two factors. In addi-
tion, the diagnosis of HCY infection was made 
serologically throughout, but reverse-transcriptase 
polymerase chain reaction was not available for all 
patients. Consequently, information on serum HCY 
RNA levels was not available in enough cases to 
warrant conclusions. However, these shortcomings 
did not undermine our observation that IFN-o: 
treatment could be administered to liver allograft 
recipients without an unacceptable increase in 
acute rejection. 
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